Quantcast

Latest PharmAthene Inc. Stories

2014-09-10 08:32:30

ANNAPOLIS, Md., Sept. 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the...

2014-09-09 08:33:14

ANNAPOLIS, Md., Sept. 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax(®) anthrax vaccine program were presented at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. In a poster presentation entitled, "Enhanced Next Generation rPA Vaccine Induces Immunogenicity and Efficacy at Least Equivalent to AVA in the New Zealand White (NZW) Rabbit Model for Anthrax," Dr....

2014-09-08 12:21:08

ANNAPOLIS, Md., Sept. 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the following investment conferences. Event: Rodman & Renshaw 16(th) Annual Global Investment Conference Date: Tuesday, September 9, 2014 Place: New York Palace Hotel, New York, NY Time: 11:40 a.m. EDT; Kennedy...

2014-09-08 12:20:37

Companies Combine Expertise and Resources to Advance Medical Countermeasures Development and Manufacturing ANNAPOLIS, Md. and ALACHUA, Fla., Sept. 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its...

2014-08-10 08:20:42

Court Also Awards Prejudgment Interest and Reasonable Attorneys' and Expert Witness Fees ANNAPOLIS, Md., Aug. 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that on August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA Technologies, Inc.'s smallpox antiviral, Tecovirimat (formerly known as ST-246 and Arestvyr(TM)). In addition, the...

2014-08-04 16:21:18

ANNAPOLIS, Md., Aug. 4, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the second quarter of 2014. For the three months ended June 30, 2014, PharmAthene recognized revenue of approximately $3.7 million, compared to approximately $4.3 million for the corresponding period in 2013. Revenue was derived primarily from contracts with...

2014-06-09 12:23:15

ANNAPOLIS, Md., June 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells. PharmAthene is initially developing rBChE as a pre- and post-exposure therapy for military and civilian victims of nerve agent attacks. "Organophosphorus compounds, including...

2014-06-04 12:29:22

ANNAPOLIS, Md., June 4, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax(®) anthrax vaccine program were recently presented at the 2014 U.S. Food and Drug Administration (FDA) Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium in Silver Spring, MD. In a presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax(®)) Provides Protection Equivalent to BioThrax(®) Against Lethal Challenge with Bacillus...

2014-05-29 12:28:35

ANNAPOLIS, Md., May 29, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax(®) anthrax vaccine program were presented at the 114(th) General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts. In a poster presentation entitled "Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine," Dr. Bradford Powell,...

2014-05-08 16:21:24

ANNAPOLIS, Md., May 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the first quarter of 2014. For the three months ended March 31, 2014, PharmAthene recognized revenue of approximately $3.7 million, compared to approximately $6.5 million for the corresponding period in 2013. Revenue was derived primarily from contracts with...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'